Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Praxis Precision Medicines (PRAX) Share-based Compensation (2022 - 2025)

Praxis Precision Medicines (PRAX) has 4 years of Share-based Compensation data on record, last reported at $9.9 million in Q4 2025.

  • For Q4 2025, Share-based Compensation rose 15.9% year-over-year to $9.9 million; the TTM value through Dec 2025 reached $33.9 million, down 17.94%, while the annual FY2025 figure was $33.9 million, 17.94% down from the prior year.
  • Share-based Compensation reached $9.9 million in Q4 2025 per PRAX's latest filing, up from $7.4 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $14.5 million in Q1 2024 and bottomed at $5.7 million in Q4 2023.
  • Average Share-based Compensation over 4 years is $8.0 million, with a median of $7.6 million recorded in 2022.
  • Peak YoY movement for Share-based Compensation: surged 115.72% in 2024, then crashed 40.1% in 2025.
  • A 4-year view of Share-based Compensation shows it stood at $6.4 million in 2022, then decreased by 10.05% to $5.7 million in 2023, then skyrocketed by 49.76% to $8.6 million in 2024, then rose by 15.9% to $9.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Share-based Compensation were $9.9 million in Q4 2025, $7.4 million in Q3 2025, and $7.8 million in Q2 2025.